Patents by Inventor George F. Schreiner

George F. Schreiner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6342495
    Abstract: The invention concerns the use of agonists and antagonists of peripheral-type benzodiazcpine receptors (PTBR) in the diagnosis and treatment of cardiac hypertrophy and other circulatory conditions. The invention specifically concerns the use of PTBR antagonists in the prevention or treatment of decompensated cardiac hypertrophy and, eventually, heart failure. The invention also concerns the use of PTBR agonists in the management of conditions calling for increased blood flow or cardiac output, including injury or functional compromise of the heart, increased demand for physical exercise, or an acquired or inherited predisposition to cardiac contractile disfunction. Pharmaceutical compositions for the treatment of such conditions and screening methods to identify PTBR agonists and antagonists are also included.
    Type: Grant
    Filed: December 15, 1999
    Date of Patent: January 29, 2002
    Assignee: Scios, Inc.
    Inventors: Alison Joly, George F. Schreiner, Lawrence W. Stanton, R. Tyler White
  • Patent number: 6340685
    Abstract: A compound of the formula: and the pharmaceutically acceptable salts thereof, wherein each of Z1 and Z2 is independently CR4 or N; where each R4 is independently H or is alkyl (1-6C) optionally including one or more heteroatoms selected from O, S and N and optionally substituted by one or more of halo, OR, SR, NR2, RCO, COOR, CONR2, OOCR, or NROCR where R is H or alkyl (1-6C), or by CN or ═O, or by an aliphatic or aromatic 5 or 6 membered ring optionally containing 1-2 N heteroatoms; or two R4 taken together form a bridge optionally containing a heteroatom; R1 is  wherein X1 is CO or an isostere thereof; m is 0 or 1; Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl or two 6 taken together may form an alkyene (2-3C) bridge; n is 0 or 2; Z3 is CH or N; X2 is CH, CH2 or an isostere thereof; and Ar consists of one or two phenyl moieties directly coupled to X2 optionally substituted by halo, nitro, alkyl (1-
    Type: Grant
    Filed: March 24, 1999
    Date of Patent: January 22, 2002
    Assignee: Scios, Inc.
    Inventors: Babu J. Mavunkel, John A. Lewicki, David Y. Liu, George F. Schreiner, John J. Perumattam
  • Patent number: 6277989
    Abstract: The invention is directed to methods to inhibit TGF-&bgr; and/or p38-&agr; kinase using compounds of the formula or the pharmaceutically acceptable salts thereof wherein R3 is a noninterfering substituent; each Z is CR2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R2 is independently a noninterfering substituent; L is a linker; n is 0 or 1; and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: August 21, 2001
    Assignee: Scios, Inc.
    Inventors: Sarvajit Chakravarty, Sundeep Dugar, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6184226
    Abstract: The invention describes compounds of the formula and the pharmaceutically acceptable salts thereof and the pharmaceutically acceptable salts thereof wherein each R2 is independently a noninterfering substituent; m is an integer of 0-4; Z is CH or N; R1 is H, alkyl (1-6C) or arylalkyl optionally substituted on the aryl group with 1-3 substituents independently selected from alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, —SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); n is 0, 1 or 2; Ar is phenyl, pyridyl, indolyl, or pyrimidyl, each optionally substituted with a group selected from the group consisting of optionally substituted alkyl (1-6C), halo, OR, NR2, SR, —OOCR, —NROCR, RCO, —COOR, —CONR2, SO2NR2, CN, CF3, and NO2, wherein each R is independently H or lower alkyl (1-4C); and R3 is a branched or cyclic alkyl group (5-7C) or is phenyl optionally substituted with 1-2 substi
    Type: Grant
    Filed: August 28, 1998
    Date of Patent: February 6, 2001
    Assignee: Scios Inc.
    Inventors: Sarvajit Chakravarty, John J. Perumattam, George F. Schreiner, David Y. Liu, John A. Lewicki
  • Patent number: 6130235
    Abstract: The invention is directed to compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof wherein Ar.sup.1 is indole, benzimidazole, or benzotriazole, optionally substituted with lower alkyl (1-4C), halo, or lower alkoxy (1-4C);X.sup.1 is CO or an isostere thereof;Y is optionally substituted alkyl, optionally substituted aryl, or optionally substituted arylalkyl;n is 0 or 1;Z is CH or N;X.sup.2 is CH, CH.sub.2 or an isostere thereof; andAr.sup.2 consists of one or two phenyl moieties directly coupled to X.sup.2 and optionally substituted by halo, nitro, alkyl (1-6C), CN or CF.sub.3, or by RCO, COOR, CONR.sub.2, NR.sub.2, OR or SR, wherein R is H or alkyl (1-6C) or by phenyl, itself optionally substituted by the foregoing substituents;with the proviso that if Z is N, X.sup.1 is CO, and Ar.sup.1 is indole, Ar.sup.1 must be coupled to X.sup.1 through the 2-, 5-, 6- or 7-position.These compounds are useful in the treatment of conditions associated with inflammation.
    Type: Grant
    Filed: August 3, 1998
    Date of Patent: October 10, 2000
    Assignee: Scios Inc.
    Inventors: Babu J. Mavunkel, John A. Lewicki, David Y. Liu, George F. Schreiner
  • Patent number: 5869537
    Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
    Type: Grant
    Filed: May 9, 1997
    Date of Patent: February 9, 1999
    Assignee: CV Therapeutics
    Inventors: George F. Schreiner, Louis G. Lange, III
  • Patent number: 5840875
    Abstract: This invention is a method for treating diseases involving the mammalian kidney proximal tubule epithelium with naked antisense oligonucleotides and antisense compositions against the mRNA of mammalian kidney epithelial proteins.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: November 24, 1998
    Assignee: C.V. Therapeutics
    Inventors: George F. Schreiner, Timothy W. Meyer, Rainer Oberbauer
  • Patent number: 5789416
    Abstract: A substituted N.sup.6 -oxa, thia, thioxa and azacycloalkyl substituted adenosine derivative and a method for using the composition as an A.sub.1 heart adenosine receptor.
    Type: Grant
    Filed: August 27, 1996
    Date of Patent: August 4, 1998
    Assignee: CV Therapeutics
    Inventors: Robert T. Lum, Jurg R. Pfister, Steven R. Schow, Michael M. Wick, Marek G. Nelson, George F. Schreiner
  • Patent number: 5668139
    Abstract: Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 16, 1997
    Assignee: University of Flordia Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, Jurg R. Pfister, George F. Schreiner
  • Patent number: 5663450
    Abstract: This invention encompasses a substantially homogeneous lipid chemoattractant released from stressed mammalian tissue which is a neutral lipid which is acid labile and stable to base and is stable in boiling water. This lipid recruits macrophages but not neutrophils to stressed tissue. The invention also encompasses a method for detecting injured tissue by detecting the presence of the above described lipid chemoattractant in body fluids such as urine, serum and saliva. The invention also includes a method for reducing recruitment of macrophages to injured tissue by reducing the amount of the above lipid chemoattractant or by blocking the interaction of this lipid chemoattractant with its macrophage binding site. The addition of this lipid chemoattractant to injured skin tissue promotes healing.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: September 2, 1997
    Assignee: CV Therapeutics
    Inventors: George F. Schreiner, Louis G. Lange, III
  • Patent number: 5631260
    Abstract: Xanthine derivatives, and compositions comprising those compounds, are potent selective antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias. The compounds, specifically, are C-8 epoxide derivatives of xanthine having the general formulae of: ##STR1## wherein R.sub.1 and R.sub.2 are the same or different, and can be H or an alkyl group of 1-4 carbons, and n=0-4; and ##STR2## wherein R.sub.1 and R.sub.2 are the same or different, and can be H or an alkyl group of 1-4 carbons, R.sub.3 is either O or (CH.sub.2).sub.1-4, and n=0-4.
    Type: Grant
    Filed: October 28, 1994
    Date of Patent: May 20, 1997
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Luiz Belardinelli, Ray Olsson, Stephen Baker, Peter J. Scammells, Peter G. Milner, J urg R. Pfister, George F. Schreiner